Biocon Malaysia Plant Gets 483 for Sterility, Testing, Quality Control Issues

A July 10-20 FDA inspection of a Biocon manufacturing facility in Malaysia turned up eight observations including a repeat observation of failure to follow procedures that prevent microbiological contamination of drugs intended to be sterile, and inadequate review and investigation of failed batches.
Source: Drug Industry Daily

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.